Research ExplorerPublicationsDeterminants of COVID-19 disease severity in patients with c...

Determinants of COVID-19 disease severity in patients with cancer

Standard

Determinants of COVID-19 disease severity in patients with cancer. / Robilotti, Elizabeth V; Babady, N Esther; Mead, Peter A; Rolling, Thierry; Perez-Johnston, Rocio; Bernardes, Marilia; Bogler, Yael; Caldararo, Mario; Figueroa, Cesar J; Glickman, Michael S; Joanow, Alexa; Kaltsas, Anna; Lee, Yeon Joo; Lucca, Anabella; Mariano, Amanda; Morjaria, Sejal; Nawar, Tamara; Papanicolaou, Genovefa A; Predmore, Jacqueline; Redelman-Sidi, Gil; Schmidt, Elizabeth; Seo, Susan K; Sepkowitz, Kent; Shah, Monika K; Wolchok, Jedd D; Hohl, Tobias M; Taur, Ying; Kamboj, Mini.

In: NAT MED, Vol. 26, No. 8, 08.2020, p. 1218-1223.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Robilotti, EV, Babady, NE, Mead, PA, Rolling, T, Perez-Johnston, R, Bernardes, M, Bogler, Y, Caldararo, M, Figueroa, CJ, Glickman, MS, Joanow, A, Kaltsas, A, Lee, YJ, Lucca, A, Mariano, A, Morjaria, S, Nawar, T, Papanicolaou, GA, Predmore, J, Redelman-Sidi, G, Schmidt, E, Seo, SK, Sepkowitz, K, Shah, MK, Wolchok, JD, Hohl, TM, Taur, Y & Kamboj, M 2020, 'Determinants of COVID-19 disease severity in patients with cancer', NAT MED, vol. 26, no. 8, pp. 1218-1223. https://doi.org/10.1038/s41591-020-0979-0

APA

Robilotti, E. V., Babady, N. E., Mead, P. A., Rolling, T., Perez-Johnston, R., Bernardes, M., Bogler, Y., Caldararo, M., Figueroa, C. J., Glickman, M. S., Joanow, A., Kaltsas, A., Lee, Y. J., Lucca, A., Mariano, A., Morjaria, S., Nawar, T., Papanicolaou, G. A., Predmore, J., ... Kamboj, M. (2020). Determinants of COVID-19 disease severity in patients with cancer. NAT MED, 26(8), 1218-1223. https://doi.org/10.1038/s41591-020-0979-0

Vancouver

Robilotti EV, Babady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardes M et al. Determinants of COVID-19 disease severity in patients with cancer. NAT MED. 2020 Aug;26(8):1218-1223. https://doi.org/10.1038/s41591-020-0979-0

Bibtex

@article{165c0a71dded440c9cb00fd9ac5b4052,
title = "Determinants of COVID-19 disease severity in patients with cancer",
abstract = "As of 10 April 2020, New York State had 180,458 cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and 9,385 reported deaths. Patients with cancer comprised 8.4% of deceased individuals1. Population-based studies from China and Italy suggested a higher coronavirus disease 2019 (COVID-19) death rate in patients with cancer2,3, although there is a knowledge gap as to which aspects of cancer and its treatment confer risk of severe COVID-194. This information is critical to balance the competing safety considerations of reducing SARS-CoV-2 exposure and cancer treatment continuation. From 10 March to 7 April 2020, 423 cases of symptomatic COVID-19 were diagnosed at Memorial Sloan Kettering Cancer Center (from a total of 2,035 patients with cancer tested). Of these, 40% were hospitalized for COVID-19, 20% developed severe respiratory illness (including 9% who required mechanical ventilation) and 12% died within 30 d. Age older than 65 years and treatment with immune checkpoint inhibitors (ICIs) were predictors for hospitalization and severe disease, whereas receipt of chemotherapy and major surgery were not. Overall, COVID-19 in patients with cancer is marked by substantial rates of hospitalization and severe outcomes. The association observed between ICI and COVID-19 outcomes in our study will need further interrogation in tumor-specific cohorts.",
author = "Robilotti, {Elizabeth V} and Babady, {N Esther} and Mead, {Peter A} and Thierry Rolling and Rocio Perez-Johnston and Marilia Bernardes and Yael Bogler and Mario Caldararo and Figueroa, {Cesar J} and Glickman, {Michael S} and Alexa Joanow and Anna Kaltsas and Lee, {Yeon Joo} and Anabella Lucca and Amanda Mariano and Sejal Morjaria and Tamara Nawar and Papanicolaou, {Genovefa A} and Jacqueline Predmore and Gil Redelman-Sidi and Elizabeth Schmidt and Seo, {Susan K} and Kent Sepkowitz and Shah, {Monika K} and Wolchok, {Jedd D} and Hohl, {Tobias M} and Ying Taur and Mini Kamboj",
year = "2020",
month = aug,
doi = "10.1038/s41591-020-0979-0",
language = "English",
volume = "26",
pages = "1218--1223",
journal = "NAT MED",
issn = "1078-8956",
publisher = "NATURE PUBLISHING GROUP",
number = "8",

}

RIS

TY - JOUR

T1 - Determinants of COVID-19 disease severity in patients with cancer

AU - Robilotti, Elizabeth V

AU - Babady, N Esther

AU - Mead, Peter A

AU - Rolling, Thierry

AU - Perez-Johnston, Rocio

AU - Bernardes, Marilia

AU - Bogler, Yael

AU - Caldararo, Mario

AU - Figueroa, Cesar J

AU - Glickman, Michael S

AU - Joanow, Alexa

AU - Kaltsas, Anna

AU - Lee, Yeon Joo

AU - Lucca, Anabella

AU - Mariano, Amanda

AU - Morjaria, Sejal

AU - Nawar, Tamara

AU - Papanicolaou, Genovefa A

AU - Predmore, Jacqueline

AU - Redelman-Sidi, Gil

AU - Schmidt, Elizabeth

AU - Seo, Susan K

AU - Sepkowitz, Kent

AU - Shah, Monika K

AU - Wolchok, Jedd D

AU - Hohl, Tobias M

AU - Taur, Ying

AU - Kamboj, Mini

PY - 2020/8

Y1 - 2020/8

N2 - As of 10 April 2020, New York State had 180,458 cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and 9,385 reported deaths. Patients with cancer comprised 8.4% of deceased individuals1. Population-based studies from China and Italy suggested a higher coronavirus disease 2019 (COVID-19) death rate in patients with cancer2,3, although there is a knowledge gap as to which aspects of cancer and its treatment confer risk of severe COVID-194. This information is critical to balance the competing safety considerations of reducing SARS-CoV-2 exposure and cancer treatment continuation. From 10 March to 7 April 2020, 423 cases of symptomatic COVID-19 were diagnosed at Memorial Sloan Kettering Cancer Center (from a total of 2,035 patients with cancer tested). Of these, 40% were hospitalized for COVID-19, 20% developed severe respiratory illness (including 9% who required mechanical ventilation) and 12% died within 30 d. Age older than 65 years and treatment with immune checkpoint inhibitors (ICIs) were predictors for hospitalization and severe disease, whereas receipt of chemotherapy and major surgery were not. Overall, COVID-19 in patients with cancer is marked by substantial rates of hospitalization and severe outcomes. The association observed between ICI and COVID-19 outcomes in our study will need further interrogation in tumor-specific cohorts.

AB - As of 10 April 2020, New York State had 180,458 cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and 9,385 reported deaths. Patients with cancer comprised 8.4% of deceased individuals1. Population-based studies from China and Italy suggested a higher coronavirus disease 2019 (COVID-19) death rate in patients with cancer2,3, although there is a knowledge gap as to which aspects of cancer and its treatment confer risk of severe COVID-194. This information is critical to balance the competing safety considerations of reducing SARS-CoV-2 exposure and cancer treatment continuation. From 10 March to 7 April 2020, 423 cases of symptomatic COVID-19 were diagnosed at Memorial Sloan Kettering Cancer Center (from a total of 2,035 patients with cancer tested). Of these, 40% were hospitalized for COVID-19, 20% developed severe respiratory illness (including 9% who required mechanical ventilation) and 12% died within 30 d. Age older than 65 years and treatment with immune checkpoint inhibitors (ICIs) were predictors for hospitalization and severe disease, whereas receipt of chemotherapy and major surgery were not. Overall, COVID-19 in patients with cancer is marked by substantial rates of hospitalization and severe outcomes. The association observed between ICI and COVID-19 outcomes in our study will need further interrogation in tumor-specific cohorts.

U2 - 10.1038/s41591-020-0979-0

DO - 10.1038/s41591-020-0979-0

M3 - SCORING: Journal article

C2 - 32581323

VL - 26

SP - 1218

EP - 1223

JO - NAT MED

JF - NAT MED

SN - 1078-8956

IS - 8

ER -